Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice

Author:

Bolliger Daniel,Szlam Fania,Suzuki Nobuaki,Matsushita Tadashi,Tanaka Kenichi

Abstract

SummaryDecreased levels of factor VIII (FVIII) limit the amount of thrombin generated at the site of injury, but not the rate that thrombin is neutralised by antithrombin (AT). We hypothesised that FVIII-deficient mice with heterozygous AT deficiency will demonstrate increased thrombin generation and therefore less in vivo bleeding compared to FVIII-deficient mice with normal AT levels. Therefore, we performed tail bleeding experiments in wild-type (WT), heterozygous AT deficient (AT+/-) mice, FVIII-deficient (FVIII-/-) mice, and FVIII-deficient mice with heterozygous AT deficiency (FVIII-/-/AT+/-). Amount of bleeding was assessed by measuring absorbance of haemoglobin released from lysed red blood cells collected after tail transection. In addition, we measured thrombin generation, activated partial thromboplastin time (aPTT), and AT activity in plasma from the different mice groups. Tail bleeding was significantly reduced in FVIII-/-/AT+/- mice compared to FVIII-/- mice. On the other hand, there was no difference in tail bleeding between AT+/- and wild-type mice. Thrombin generation was dependent on the mice geno-type, and increased in the following order: FVIII-/- < FVIII-/-/AT+/- < WT < AT+/-. The aPTT was not influenced by reduced AT activity (i.e. AT+/- genotype), but was significantly prolonged in FVIII-/- and FVIII-/-/AT+/- mice. Using FVIII-deficient mice as an in vivo murine model of reduced thrombin generation, we demonstrated that moderately reduced AT levels increase thrombin generation and decrease bleeding after traumatic tail vessel injury. In agreement with congenital thrombotic conditions, our data elucidate that bleeding phenotypes can be modulated by the balance between procoagulant and anticoagulant proteins.

Funder

Department of Anaesthesia

Publisher

Georg Thieme Verlag KG

Subject

Hematology

Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?;Expert Opinion on Pharmacotherapy;2024-07-23

2. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05

3. Antithrombin-lowering in hemophilia: a closer look at fitusiran;Research and Practice in Thrombosis and Haemostasis;2023-05

4. Thrombin generation and implications for hemophilia therapies: A narrative review;Research and Practice in Thrombosis and Haemostasis;2023-01

5. Early stage clinical trials for the treatment of hemophilia A;Expert Opinion on Investigational Drugs;2022-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3